These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16480172)

  • 1. A clinical crossroads for MDMA.
    Guillot C
    J Psychoactive Drugs; 2005 Dec; 37(4):445-7. PubMed ID: 16480172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.
    McCann UD; Eligulashvili V; Ricaurte GA
    Neuropsychobiology; 2000; 42(1):11-6. PubMed ID: 10867551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves.
    Parrott AC
    Neuropsychobiology; 2004; 50(4):329-35. PubMed ID: 15539865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
    Biezonski DK; Meyer JS
    J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues.
    Lyvers M
    Drug Alcohol Rev; 2006 May; 25(3):269-76. PubMed ID: 16753651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
    Gouzoulis-Mayfrank E; Daumann J
    J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDMA ("ecstasy") abuse as an example of dopamine neuroplasticity.
    Schenk S
    Neurosci Biobehav Rev; 2011 Apr; 35(5):1203-18. PubMed ID: 21184779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.
    Baumann MH; Wang X; Rothman RB
    Psychopharmacology (Berl); 2007 Jan; 189(4):407-24. PubMed ID: 16541247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of MDMA ("ecstasy")-induced neurotoxicity to long-lasting psychomotor stimulation in mice.
    Itzhak Y; Ali SF; Achat CN; Anderson KL
    Psychopharmacology (Berl); 2003 Mar; 166(3):241-8. PubMed ID: 12590354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
    Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ecstasy: are animal data consistent between species and can they translate to humans?
    Easton N; Marsden CA
    J Psychopharmacol; 2006 Mar; 20(2):194-210. PubMed ID: 16510478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms.
    Lyles J; Cadet JL
    Brain Res Brain Res Rev; 2003 May; 42(2):155-68. PubMed ID: 12738056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users.
    Croft RJ; Klugman A; Baldeweg T; Gruzelier JH
    Am J Psychiatry; 2001 Oct; 158(10):1687-92. PubMed ID: 11579003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research.
    Curran HV
    Neuropsychobiology; 2000; 42(1):34-41. PubMed ID: 10867554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term neuronal damage and recovery after a single dose of MDMA: expression and distribution of serotonin transporter in the rat brain.
    Kirilly E
    Neuropsychopharmacol Hung; 2010 Sep; 12(3):413-23. PubMed ID: 20962361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation between serotonin neurotoxicity and brain-derived neurotrophic factor induction following neonatal MDMA exposure in rats.
    Piper BJ; Farelli JD; Meyer JS
    Dev Neurosci; 2009; 31(1-2):90-4. PubMed ID: 19372690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.
    Parrott AC
    Hum Psychopharmacol; 2013 Jul; 28(4):289-307. PubMed ID: 23881877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.